Related Experiment Video

Updated: May 22, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy

Guoguang Wang1, Wei Li, Xiaohua Lu

  • 1Department of Pathophysiology, Wannan Medical College, China. guoguangw1226@sina.com

Journal of Diabetes and Its Complications
|May 26, 2012
PubMed

Insights

Luteolin demonstrates cardioprotective effects against diabetic cardiomyopathy by reducing oxidative stress. This natural compound helps mitigate cardiac dysfunction in diabetes through its antioxidant properties.

Area of Science:

  • Cardiovascular Research
  • Diabetology
  • Pharmacology

Background:

  • Diabetic cardiomyopathy is a significant complication of diabetes mellitus.
  • Oxidative stress plays a critical role in the pathogenesis of diabetic cardiomyopathy.
  • Current therapeutic options for diabetic cardiomyopathy are limited.

Purpose of the Study:

  • To investigate the cardioprotective effects of luteolin against diabetic cardiomyopathy.
  • To assess the impact of luteolin on markers of oxidative stress in diabetic hearts.
  • To explore the underlying mechanisms of luteolin's action, including its effects on lipid metabolism and key signaling pathways.

Main Methods:

  • Diabetic cardiomyopathy was induced in rats using streptozotocin (STZ).
  • Left ventricular hemodynamic analysis was performed.
  • Myocardial oxidative stress markers, including superoxide dismutase (SOD) activity and malondialdehyde (MDA) levels, were measured.
  • Protein levels of Akt/PKB phosphorylation, heme oxygenase-1 (HO-1), and connective tissue growth factor (CTGF) were assessed using Western blot.

Main Results:

  • Diabetic rats exhibited increased serum lipids (TG, TC, LDL), elevated MDA, CK, LDH, and myocardial CTGF, along with decreased HDL, SOD, and Akt phosphorylation compared to controls.
  • Luteolin treatment significantly improved these parameters, reducing lipid levels, MDA, CK, LDH, and CTGF, while increasing HDL, SOD, and Akt phosphorylation.

Conclusions:

  • Luteolin confers significant cardioprotective effects against diabetic cardiomyopathy.
  • These protective effects are mediated by the attenuation of myocardial oxidative stress.
  • Luteolin's antioxidant properties are likely responsible for its beneficial actions in diabetes-induced cardiac dysfunction.
Abstract

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...